Concepedia
Statistics
Publications
6
Citations
1.1K
H-Index
Active since
2007
Affiliations
Novartis (United States)(Current)
Harvard University
Novartis (Switzerland)
Paul Fordjour is an author at Novartis (United States) specializing in molecular oncology, oncology, and pharmacology.
Publications per year
2007–2020
Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
Silvia Buonamici, Juliet Williams, Michael Morrissey et al. · Science Translational Medicine · 2010 · 554 citations
Medicine, Oncology, Pharmacology +16
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors
Leila Dardaei, Hui Qin Wang, Manrose Singh et al. · Nature Medicine · 2018 · 202 citations · Full text
Contribution of Polycomb Homologues Bmi-1 and Mel-18 to Medulloblastoma Pathogenesis
Dmitri Wiederschain, Lin Chen, Brett V. Johnson et al. · Molecular and Cellular Biology · 2007 · 123 citations · Full text
Life Sciences, Cancer Biology, Molecular Biology +17
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors
Kelli‐Ann Monaco, Scott Delach, Jing Yuan et al. · Clinical Cancer Research · 2020 · 88 citations · Full text
Medicine, Oncology, Pharmacology +17
The Polycomb Group Protein Bmi-1 Is Essential for the Growth of Multiple Myeloma Cells
Zainab Jagani, Dmitri Wiederschain, Alice Loo et al. · Cancer Research · 2010 · 66 citations
1–5 of 6